LiBReCa: Observational Study on Rectal Cancer to Verify if Response After Chemo-radiotherapy Can be Predicted With a Particular Blood Test.

• Sponsor: Dimitri Christoforidis (Other)
• Overall Status: Terminated
• CT.gov ID: NCT03699410
• Collaborator: Clinical Trial Unit Ente Ospedaliero Cantonale (Other)
• Enrollment: 25
• Locations: 2
• Actual Duration (Months): 25.8
• Patients Per Site: 12.5
• Patients Per Site Per Month: 0.5

Study Details

Study Description

Brief Summary

Research project for patients with locally advanced rectal cancer in which biological material and health-related personal data are collected.

The aim is to investigate if an additional method (liquid biopsies) can predict the response after chemo-radiotherapy and before surgery.

Condition or Disease	Intervention/Treatment	Phase
Locally Advanced Rectal Cancer	Radiation: Neoadjuvant radiotherapy; Drug: Neoadjuvant chemotherapy; Procedure: Radical surgery

Detailed Description

The standard treatment for locally advanced rectal cancer (T3 -T4 and / or N+) is neoadjuvant (pre-operative) chemo-radiotherapy (nCRT) followed by radical surgery. In patients after complete response following nCRT, surgery may not add any survival benefit but it is still performed.

Since clinical complete response has only partial concordance with pathological complete response, an additional method that helps identify those patients with a true complete response is needed to avoid unnecessary surgery and its associated potential complications..

The hypothesis underlying this study is that the quantitative and qualitative evaluation of circulating tumor DNA (ctDNA) of liquid biopsy, based on the amount of ctDNA or on the detection of specific gene alterations respectively, may be directly correlated to the clinical, histopathological and radiological response of the tumor to nCRT.

This study will not interfere with the patient's routine treatment pathway and there will be no deviation from the standard of care. The only additional study intervention will be the collection of blood samples at 6 different time points which can be combined with the regular blood examination performed during the treatment.

At the time of diagnosis, tumor staging and histopathology on tumor biopsy will be performed. Patients will receive standardized neoadjuvant therapy and will be operated after an observational period of 10 weeks. Peripheral blood sample will be collected at 6 time points: pre-nCRT, at the end of the nCRT, at 4th and 7th week post-CRT, on the day of the surgery (before surgical resection), on the post-operative day 5 (in hospital). Mesenteric blood sample will be collected intra-operatively on the day of the surgery. Tumor sampling will be performed during tumor staging, as standard of care, and on the resection specimen. A combined qualitative and quantitative approach for the molecular characterization of tissue and liquid biopsy using next-generation sequencing will be carried out.

Study Design

• Study Type: Observational
• Actual Enrollment: 25 participants
• Observational Model: Case-Only
• Time Perspective: Prospective
• Official Title: A Proof-of-concept, Prospective, Observational Study to Investigate the Value of Liquid Biopsies to Predict Tumor Response After Neoadjuvant Chemo-radiotherapy in Patients With Locally Advanced Rectal Cancer: the LiBReCa Study
• Actual Study Start Date: Aug 28, 2018
• Actual Primary Completion Date: Oct 20, 2020
• Actual Study Completion Date: Oct 20, 2020

Outcome Measures

Primary Outcome Measures

1. Negative Prognostic Value (NPV) [day of surgery]

   NPV of the liquid biopsy of ctDNA drawn from the mesenteric and peripheral blood

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Age ≥ 18 years old

• Locally advanced rectal cancer (T3 or T4, and/or N+) requiring long course nCRT (as decided by the regional tumor board)

• Patient fit for surgery and treated with curative intent

• Willingness to complete all clinical and radiological examinations foreseen by the study

• Availability of tissue specimen for molecular characterization at baseline

• Written informed consent

Exclusion Criteria:

• Presence of metastases

• Insufficient material on the tissue biopsy to be left in archives of the Cantonal Institute of Pathology for further evaluations/analyses

• Insufficient amount of tumor cells in the tissue biopsy for the molecular characterization

• Inability to consent and follow the procedures of the study

• Women who are pregnant or breast feeding

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Regional Hospital of Lugano	Lugano		Switzerland	6900
2	Clinica Luganese Moncucco	Lugano		Switzerland	6903

Sponsors and Collaborators

• Dimitri Christoforidis
• Clinical Trial Unit Ente Ospedaliero Cantonale

Investigators

• Principal Investigator: Dimitri Christoforidis, Surgery and Visceral Surgery Departments Regional Hospital of Lugano

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Dimitri Christoforidis, Deputy Chief of the Surgery and Visceral Surgery Departments, Ente Ospedaliero Cantonale, Bellinzona
• ClinicalTrials.gov Identifier: NCT03699410
• Other Study ID Numbers: ORL-CHIR-002
• First Posted: Oct 9, 2018
• Last Update Posted: Oct 13, 2021
• Last Verified: Oct 1, 2021

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Rectal Neoplasms

Study Results

No Results Posted as of Oct 13, 2021